Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study

[1] De Wit S(2008)Incidence and risk factors for new onset diabetes in HIV-infected patients. The data collection on adverse events of anti-HIV drugs (D: A: D) study Diabetes Care 31 1224-1229

[2] Sabin CA(2005)Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors JAC 55 800-804

[3] Weber R(2007)Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens J Acquir Immune Defic Syndr 45 34-42

[4] Worm SW(1999)Diagnosis, prediction and natural course of HIV-1 protease-inhibitor associated lipodystrophy hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 2093-2099

[5] Reiss P(2008)Metabolic changes in protease inhibitor-naïve patients with lopinavir/ritonavir J Acquir Immune Defic Syndr 48 628-629

[6] Cazanave C(2008)No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: A placebo-controlled trial Clinical Infectious Disease 47 567-574

[7] El-Sadr C(2010)The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers AIDS 24 265-270

[8] Monforte W(2006)Single-dose lopinavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers Clin Infect Dis 43 658-660

[9] Fontas A(2003)Correlation between lopinavir plasma levels and lipid abnormalities in patients taking Lopinavir/ritonavir AIDS Patient Care STDS 17 443-445

[10] Law E(2003)Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens J Acquir Immune Defic Syndr 33 594-600

[1] De Wit S(2008)Incidence and risk factors for new onset diabetes in HIV-infected patients. The data collection on adverse events of anti-HIV drugs (D: A: D) study Diabetes Care 31 1224-1229

[2] Sabin CA(2005)Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors JAC 55 800-804

[3] Weber R(2007)Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens J Acquir Immune Defic Syndr 45 34-42

[4] Worm SW(1999)Diagnosis, prediction and natural course of HIV-1 protease-inhibitor associated lipodystrophy hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 2093-2099

[5] Reiss P(2008)Metabolic changes in protease inhibitor-naïve patients with lopinavir/ritonavir J Acquir Immune Defic Syndr 48 628-629

[6] Cazanave C(2008)No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: A placebo-controlled trial Clinical Infectious Disease 47 567-574

[7] El-Sadr C(2010)The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers AIDS 24 265-270

[8] Monforte W(2006)Single-dose lopinavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers Clin Infect Dis 43 658-660

[9] Fontas A(2003)Correlation between lopinavir plasma levels and lipid abnormalities in patients taking Lopinavir/ritonavir AIDS Patient Care STDS 17 443-445

[10] Law E(2003)Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens J Acquir Immune Defic Syndr 33 594-600